Dianthus Therapeutics, Inc.
NASDAQ:DNTHBiotechnology
-$1.03 today
- Market cap
- $4.73B
- Beta
- 0.07
- P/E (TTM)
- -343.0
- EPS (TTM)
- -$0.24
Volume 0.84M
Average 0.82M
DNTH Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Dianthus Therapeutics, Inc.NASDAQ: DNTH
Financing Cash Flow · Q2 FY2026 · quarter ended Jun 2026
Financing cash flow grows, but more slowly than its trailing trend
Q2 FY2026 financing cash flow of $10.38M rose 1727.5% year over year, behind the +2428.7% change in trailing-twelve-month financing cash flow. Sequentially, it fell 98.6% from the prior quarter. Over 3 fiscal years it compounded at +42.6% a year.
Context
- Financing cash flow amounted to 13758.6% of revenue in FY2025, up 9658.8 pp from a year earlier.
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +1727.5% toward the trailing-twelve-month pace of +2428.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 280.13M USD
- Year-over-year change
- +9.6%
- 4-year CAGR
- +33.0%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 280.13M | +9.6% |
| FY2024 | 2024-12-31 | 255.62M | +91.4% |
| FY2023 | 2023-12-31 | 133.57M | +38.2% |
| FY2022 | 2022-12-31 | 96.68M | +7.9% |
| FY2021 | 2021-12-31 | 89.6M | — |
Financing Cash Flow vs competitors
How DNTH compares with its peers on the latest reported figures
- DNTH's LTM Jun 2026 financing cash flow of $1.03B is the largest of the 10 companies compared; the peer median is $15.64M.
- Its year-over-year change of +2428.7% is the highest of 10, against a peer median of +24.1%.
- Financing cash flow amounts to 54053.9% of revenue for DNTH, versus a peer median of 1294.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.03B | +2428.7% | +42.6% | 54053.9% | |
| LTM Sep 2026 | $596.22M | +24.1% | +103.3% | 8403.4% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $360.93M | +53.0% | -72.7% | 4878.8% |
| LTM Jun 2026 | $292.94M | -15.9% | +44.7% | — | |
| LTM Mar 2026 | $103.52M | +40.9% | +6.8% | — | |
| LTM Mar 2026 | $102.81M | -191.7% | — | 44.2% | |
| LTM Mar 2026 | $15.64M | -86.7% | — | 881.2% | |
| LTM Mar 2026 | $5.67M | +234.8% | — | 10.6% | |
| FY2025 | $1.09M | +381.5% | — | 1707.8% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $342K | -100.2% | — | — |
| Peer median (excluding DNTH) | $15.64M | +24.1% | +25.8% | 1294.5% | |
Competitors are the stored peer set for DNTH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (71.14M) | (28.48M) | (43.56M) | (84.97M) | (162.34M) |
| Depreciation & Amortization | 2.02M | 147K | 355K | 412K | 428K |
| Deferred Income Tax | 0 | 0 | (661K) | 0 | 0 |
| Stock-Based Compensation | 0 | 1.52M | 2.9M | 12.89M | 22.79M |
| Change in Working Capital | (1.53M) | (1.65M) | 4.86M | (351K) | 16.73M |
| Accounts Receivables | 0 | (4.16M) | 5.16M | 0 | 755K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (720K) | 2.28M | 661K | 8.19M | 11.28M |
| Other Working Capital | (806K) | 229K | (959K) | (8.54M) | 4.69M |
| Other Non-Cash Items | 11.11M | (606K) | (762K) | (6.17M) | (6.67M) |
| Operating Cash Flow | (59.53M) | (29.07M) | (36.86M) | (78.18M) | (129.06M) |
| Capital Expenditures | (1.26M) | (139K) | (110K) | (105K) | (213K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (45.31M) | (61.68M) | (57.42M) | (413.71M) | (435.01M) |
| Sales of Investments | 90M | 2M | 77.79M | 127M | 312.39M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 43.43M | (59.82M) | 20.25M | (286.81M) | (122.83M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 89.6M | 0 | 72M | 269.2M | 280.13M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (3.32M) | 61.57M | (13.58M) | 0 |
| Financing Cash Flow | 89.6M | 96.68M | 133.57M | 255.62M | 280.13M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 73.5M | 7.79M | 116.97M | (109.37M) | 28.23M |
| Free Cash Flow | (60.8M) | (29.21M) | (36.97M) | (78.29M) | (129.27M) |
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
Intrinsic Alpha fair value
Locked
Current Price
$83.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.